glp-1 obesity drug supply news today Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Medicine Association, and The Obesity Society GLP-1 Receptor Agonists Obesity Drugs

T2DM is the underlying cause of many complications, among which, cardiovascular diseases (CVDs) are mainly responsible for the high rates of morbidity and mortality

A report from PricewaterhouseCoopers found that GLP-1 drugs drove a disproportionate share of the $50 billion hike in pharmacy spending in 2024 (up from a $20 billion increase in 2023)

I., Tsoukas, G

Patients should be advised to seek immediate medical attention if they experience severe, persistent abdominal pain

Tirzepatide (Zepbound) for weight management follows the same initial titration as Mounjaro but with a maintenance dose of 15 mg weekly for maximum effect